source
- J&J and AbbVie present early trispecific antibody data for multiple myeloma at ASH meetingAt the American Society of Hematology (ASH) meeting, Johnson & Johnson and AbbVie are slated to share early clinical data on trispecific antibodies targeting multiple myeloma. These next‑generation…
- British biotech T-Therapeutics raises $133 million Series B to advance bispecific T-cell engagersT-Therapeutics, a British biotech, announced a $133 million Series B financing to advance its next-generation T-cell engager therapeutics. The round was co-led by Advent Life Sciences and the Brit…